Join
Live feed
·
PRReleasevia Quantisnow
Altimmune Inc. logo

Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD

ByQuantisnow·Wall Street's wire, on your screen.
ALT· Altimmune Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALT (Altimmune Inc.) and more on Quantisnow.